Emergency Zika Package II: Persistence of zika virus in body fluids and case-control investigation of etiologic agents associated with Guillain-Barré Syndrome
Emergency Zika Package II:
Persistence of zika virus in body fluids and case-control
investigation of etiologic agents associated with Guillain-Barré
Syndrome
New
collection (Request for a new OMB Control Number)
Approved
consistent with the understanding that associated collections
extending beyond 6 months will be submitted to OMB as a
non-emergency information collection request for formal
review.
Inventory as of this Action
Requested
Previously Approved
09/30/2016
6 Months From Approved
5,330
0
0
769
0
0
0
0
0
As part of the CDC's response to the
ongoing zika virus outbreak, two projects are being undertaken: a
case-control investigation to determine demographic
characteristics, environmental exposures, or infectious agents
associated with GBS; and a cohort study to determine the
prevalence/duration of Zika RNA in body fluids and the duration of
Zika virus IgM antibodies in serum. The intended use of this
information is to target and refine public health interventions to
arrest ongoing spread of Zika.
Zika virus (ZIKV) is a
mosquito-borne flavivirus that has recently emerged in the
Americas. Previously, outbreaks had occurred in Asia and islands in
the south Pacific. In addition to mosquito-to-human transmission,
ZIKV infections have been documented through sexual transmission,
blood transfusion, laboratory exposure, intrauterine transmission
resulting in congenital infection, and intrapartum transmission
from a viremic mother to her newborn. The justification for use of
the Emergency mechanism for the studies associated with this ICR
are as follows: Project 1: The prevalence of ZIKV RNA in various
body fluids among patients with acute ZIKV infection and the length
of time that ZIKV RNA might persist in these body fluids is not
well understood. Characterizing these parameters has implications
both for potential human-to-human transmission and for diagnosis of
ZIKV infection. Project 2: There is an urgent public health need to
understand the potential association between GBS and ZIKV
infection. Currently, increased numbers of GBS cases have been
reported in ZIKV-affected contexts, but it is not known if this is
due to ZIKV, another etiologic agent, or some
combination/interaction thereof.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.